The Dean Thinks $BCRX Could Reach Ivy League Status
November 13th, 2009 at 8:29 am Posted by The Dean
$BCRX, otherwise known as The Dean’s Swine Flu Barometer, has continued to prove to The Dean that swine flu stock picks definitely have plenty of profit potential.
BioCryst Pharmaceuticals (NASDAQ: BCRX) has developed an anti-viral influenza treatment for influenza but has received enough attention from the United States government to earn a contract to deliver 130,000 doses of the company’s Peramivir.
So far, $BCRX has received $22.5 million for 10,000 treatments, which means the company could receive an additional $270 million when the remaining doses are produced and delivered.
The Dean taught the entire CollegeStock Community about $BCRX on November 1st as part of Week 6 of The Dean’s Prerequisite Picks, when it was trading at $8.93 a share. Since then, $BCRX has spiked as high as $12.70 for a potential gain of 42%.
With the flu season heating up, The Dean thinks $BCRX and other swine flu stocks could see more profits. This is one of the main reasons that The Dean believes his upcoming swine flu stock pick is a promising find and the fact that this Ivy League Stock Pick will come in the form of an IPO could have many people excited.
